{"id":"W2104759721","doi":"10.1016/s0140-6736(13)61719-5","title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2200,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Ramucirumab; Medicine; Internal medicine; Hazard ratio; Placebo; Clinical endpoint; Gastroenterology; Cancer; Randomized controlled trial; Oncology; Surgery; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}